Novel treatments for rare cancers: the U.S. orphan drug act is delivering : a cross-sectional analysis
The U.S. Orphan Drug Act of 1983 and associated incentives have fostered delivery of novel treatments for rare cancers. Quantitative cross-sectional analysis on the U.S. Food and Drug Administration Orphan Drug Product database found that more than one-third of all orphan drug approvals address need...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2016 Mar 28
|
| In: |
The oncologist
Year: 2016, Volume: 21, Issue: 4, Pages: 487-493 |
| ISSN: | 1549-490X |
| DOI: | 10.1634/theoncologist.2015-0397 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1634/theoncologist.2015-0397 Verlag, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828121/ 
|
| Author Notes: | Clemens Stockklausner, Anette Lampert, Georg F. Hoffmann, Markus Ries |
| Summary: | The U.S. Orphan Drug Act of 1983 and associated incentives have fostered delivery of novel treatments for rare cancers. Quantitative cross-sectional analysis on the U.S. Food and Drug Administration Orphan Drug Product database found that more than one-third of all orphan drug approvals address needs of patients suffering from rare cancers. |
|---|---|
| Item Description: | Gesehen am 08.05.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1549-490X |
| DOI: | 10.1634/theoncologist.2015-0397 |